[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
High-dosage recombinant alpha 2 interferon ( rIFN -alpha 2) was used for treatment of 12 patients with metastatic adenocarcinoma of the colon or rectum. In a prospective randomised fashion either 50 X 10(6) E/m2 as 30-minute infusion on 5 consecutive days four-weekly or 20 X 10(6) E/m2 subcutaneously thrice weekly were administered. No significant regression of the tumour could be observed. Treatment side-effects such as fever, shivering and fatigue were so pronounced particularly after subcutaneous administration that no patient could be treated for longer than 8 weeks. According to these findings single use of rIFN -alpha 2 does not seem to be of use for treatment of metastatic colorectal carcinomas. Subcutaneous administration is associated with considerable side-effects which subjectively in the majority of patients were considered intolerable.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006560:Herpes Labialis / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000556:secondary
D007370:Interferon Type I; D005472:Fluorouracil
Biologischer Effekt von rekombiniertem Leukozyten-alpha 2-Interferon bei metastasierten kolorektalen Karzinomen.